Atypical Antipsychotic Prevents and Reverses Negative Symptoms in Models of Schizophrenia
Journal Title: International Neuropsychiatric Disease Journal - Year 2017, Vol 9, Issue 3
Abstract
Introduction: Negative symptoms associated with cognitive impairment as a core symptom of schizophrenia with significant poor quality of life and remain an unmet clinical need. Administration of N-methyl-D-aspartate (NMDA) receptor antagonists in rodents has been proposed as an animal model of negative symptoms in this disorder. Evidence from both animal models and human studies implicates a dysfunction of NMDA receptor function may attribute to pathophysiology of schizophrenia. Objectives: This study was undertaken to investigate the ability of sub-chronic co-administration of clozapine and haloperidol to both prevent and attenuate the social deficits induced by the NMDA receptor antagonist, phencyclidine (PCP) in the social interaction tasks. Methods: In the first test, female Sprague-Dawley rats were treated with saline, clozapine 5.0 mg/kg or haloperidol 0.05 mg/kg, 30 min later followed by either saline or PCP 2.0 mg/kg twice daily for 7 days, followed by 7 days drug free before tested in social interaction tasks. For the second test, female Sprague-Dawley rats received either vehicle or PCP 2.0 mg/kg for 7 days followed by 7 days drug free. Then rats received clozapine 5.0 mg/kg, haloperidol 0.05 mg/kg or vehicle twice daily for 7 days and were tested 120 min following the last dose of antipsychotic in social interaction tasks. Results: PCP treatment produced a significantly reduced social behaviours and that effect significantly prevented and improved by clozapine, but not haloperidol. Conclusions: These results suggest that antagonism of the consequences of reduced NMDA receptor function could contribute to the superior efficacy of atypical antipsychotic agents in improving negative symptoms in schizophrenia. These negative symptoms impairment likely reflect clinically relevant and can be used to evaluate the antipsychotic potential of new compounds on cognitive symptoms of schizophrenia.
Authors and Affiliations
Nagi F. Idris
Keywords
Related Articles
- EP ID EP308437
- DOI 10.9734/INDJ/2017/34161
- Views 111
- Downloads 0
Crosstalk between Mind and Oral Cavity: An Insight into Pathogenesis, Classification, Presentation and Management of Oral Psychosomatic Disorders
In general, the conviction is that psychological factors are important in the development of all disease. Epidemiological surveys have revealed that there are different ways in which emotional stressful stimuli can act o...
The Aquaporins: Regulator for Brain Pathophysiology
Water transport is a fundamental process contributing to human physiology and pathophysiology. Water is primarily needed for all cell types but the water does not sit in the cells it moves through in very organized way....
Practice Guidelines for Treatment of Somatic Pain and Depression
Background: Somatic pain is often associated with depression. Patients presenting with this combination can be difficult to treat and create a significant financial burden on the medical system. The mechanisms of action...
Accuracy of Hyperintense Cerebrospinal Fluid Signals (CSF) on Inversion Recovery (IR) Images of Brain in the Diagnosis of Meningitis-a Cost Effective Experience from Third World Country
Objective: To detect the diagnostic accuracy of inversion recovery sequence in detection of meningitis taking cerebrospinal fluid as the gold standard. Material and Methods: This study was conducted in Aga Khan Universit...
Evaluation of Oxidative Stress in Liver Cirrhosis Patients to Early Diagnosis of Minimal Hepatic Encephalopathy
Introduction: Minimal hepatic encephalopathy (MHE) is mildest form of the spectrum of neuropsychiatric and neurocognitive impairment in cirrhosis. Early recognition of this impairment may prevent the progression or may d...